Vol. 209

Special Feature

  • Legislation on Ensuring Safety of Regenerative Medicine in Japan
  • Regenerative Medicine Regulation in Japan: Focusing on Legislation on Ensuring Quality, Efficacy and Safety of Relevant Drugs and Devices
  • Regenerative Medicine Regulation in the US: Focusing on 21 CFR 1271 and 21st Century Cures Act
  • Liability and Shareholder Class Action of Clinical Trial for Cell Therapy: From the Perspective of Juno’s CAR-T Development and Incident

Legal Issues

  • Ethical and Legal Challenges on Expanded Use to Drugs in Ongoing Clinical Trial
  • Shakespeare's Time, EU's Directive on collective management of copyright and Cross-Border Licensing
  • Dentist Discipline in the US: Taking Washington D.C. as an Example
  • Distinction Between “Approval” and “Report for Reference”: Focusing on Article 24 and Article 32 of the University Act
  • Taiwan’s Trade Secret Regulations: Lesson from the Defend Trade Secrets Act of 2016 (DTSA)

Taiwan Law Column

  • Guidelines for Entering into a Labor Contract: Responding to the Newly Amended Article 9-1 of the Labor Standards Act
If you would like to read any of the articles, please click on the following links:
Previous Back to list Next